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S U M M A R Y
Background: A randomized, double-blind, multicenter trial was done to compare two doses of
delaﬂoxacin with tigecycline in patients with various complicated skin and skin-structure infections
(wound infections following surgery, trauma, burns, or animal/insect bites, abscesses, and cellulitis).
Methods: Patients were randomized 1:1:1 to receive delaﬂoxacin 300 mg intravenous (IV) every 12 h,
delaﬂoxacin 450 mg IV every 12 h, or tigecycline 100 mg IV  1, followed by 50 mg IV every 12 h;
randomization was stratiﬁed by infection type. Duration of therapy was 5–14 days. The primary efﬁcacy
analysis, performed on the clinically evaluable (CE) population at the test-of-cure (TOC) visit (14–21
days after the ﬁnal dose of study drug), compared clinical response rates in the delaﬂoxacin and
tigecycline arms. Clinical response rates in the two delaﬂoxacin arms were also compared.
Results: Among CE patients, clinical cure rates at TOC visit were similar in the delaﬂoxacin and
tigecycline arms (94.3%, 92.5%, and 91.2%, respectively in delaﬂoxacin 300-mg, delaﬂoxacin 450-mg,
and tigecycline arms). Overall, the most frequent adverse events were nausea, vomiting, and diarrhea;
the 300-mg delaﬂoxacin arm was the best-tolerated regimen.
Conclusions: Delaﬂoxacin was similarly effective as tigecycline for a variety of complicated skin and
skin-structure infections and was well tolerated. (Clinicaltrials.gov NCT 0719810)
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
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Complicated infections of the skin and skin structures (cSSSIs)
are common and can affect patients of all ages. Gram-positive
bacteria, in particular Staphylococcus aureus and Streptococcus
pyogenes, are the most common causative pathogens. Over the
course of the last 15–20 years, after largely being localized to
hospitals and other healthcare settings, methicillin-resistant
strains of S. aureus (MRSA) have made inroads into community-
based settings, where they have become an increasingly common
cause of skin and skin-structure infections.1–3 In 2011, the
Infectious Diseases Society of America published their ﬁrst set of* Corresponding author. Tel.: +1 619-955-5203; fax: +1 619-262-3716.
E-mail address: woriordan@estudysite.com (W. O’Riordan).
http://dx.doi.org/10.1016/j.ijid.2014.10.009
1201-9712/ 2014 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).guidelines for the treatment of MRSA infections.4 While several
agents, both oral and intravenous (IV), are cited as treatment options
for skin and skin-structure infections, a number of them have
limitations, including rapid development of resistance, inadequate
coverage of beta-hemolytic streptococci, static vs. cidal antibacterial
activity, and adverse effects such as nephrotoxicity and gastrointes-
tinal (GI) intolerance,5 all of which underscore the need for
continued development of effective drugs for MRSA.
Delaﬂoxacin (RX-3341, ABT-492, WQ-3034) is a next-generation
ﬂuoroquinolone antibiotic active against an array of Gram-positive
pathogens (methicillin-susceptible S. aureus (MSSA), MRSA, Strep-
tococcus pyogenes, and enterococci), Gram-negative pathogens
(Escherichia coli, Klebsiella spp, Pseudomonas aeruginosa, and
Neisseria gonorrhoeae), and anaerobes.6–8 Like other ﬂuoroquino-
lones, it exerts its effects via inhibition of bacterial topoisomerases
involved in maintaining appropriate DNA supercoiling andciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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ﬂoxacin (1-deoxy-1-(methylamino)-D-glucitol, 1-(6-amino-3,5-
diﬂuoro-2- pyridinyl)-8-chloro-6-ﬂuoro-7-(3-hydroxy-1-azeti-
dinyl)-4-oxo-1,4-dihydro-3-quinolinecarboxylate (salt)) appears
to enhance its potency in acidic environments, which are
characteristic of sites of infection, and thus could be a beneﬁt
when treating infections. For example, S. aureus has a high
tolerance for low pH and can survive and multiply in mildly
acidic surroundings, like the skin.9 This, coupled with the
fact that delaﬂoxacin exhibits a low probability for the
selection of resistant MRSA mutants,10 suggests that it could
be an important treatment for skin infections, including
abscesses, which are frequently caused by resistant strains of
S. aureus.
Tigecycline is a glycylcycline antibiotic active against a variety
of Gram-positive organisms, including MSSA, MRSA, and Entero-
coccus faecalis (including vancomycin-resistant strains), as well as
a broad spectrum of Gram-negative and anaerobic organisms.11
Tigecycline is US Food and Drug Administration (FDA)-approved
for cSSSIs, complicated intra-abdominal infections, and communi-
ty-acquired pneumonia.
We conducted a study comparing two different doses of
delaﬂoxacin with a standard dose of tigecycline. This study was
presented in part at the 19th European Congress of Clinical
Microbiology and Infectious Diseases.12
2. Materials and methods
This was a phase 2, multicenter, randomized, double-blind
study comparing the efﬁcacy and tolerability of two doses of
delaﬂoxacin vs. tigecycline in patients with cSSSIs (Clinicaltrials.-
gov identiﬁer NCT 0719810). This study was conducted at 14 sites
in the USA between June and September 2008. Written consent for
participation in the study was obtained from all patients, and the
study was conducted in accordance with the Declaration of
Helsinki.
2.1. Study population
Eligible patients were 18 years of age and had received a
diagnosis of cSSSI. Complicated skin or skin-structure infections
were deﬁned as those involving subcutaneous tissues or requiring
surgical intervention. Patients could have had one or more of the
following three infection types: (1) A wound infection that had
developed within 30 days of surgery, trauma, or an animal/insect
bite injury; patients were required to have either purulent
drainage from the wound or three or more of the following
symptoms: fever, swelling, erythema of 10 mm, pain, or
tenderness. (2) An abscess, without an open wound, that had
developed during the 7 days before enrollment, with purulent
drainage or a purulent aspirate; patients were required to have
evidence of a loculated ﬂuid collection that required intervention
within 48 h of enrollment and erythema and/or induration of
20 mm in diameter or tenderness. (3) Cellulitis that had
developed during the 7 days before enrollment, with advancing
edema, erythema, or induration; in addition patients must have
had at least one of the following: documented fever or reported
fever during the 3 days before enrollment, a white blood cell count
of 10  109/l or 10% band forms, or lymphangitis and adeno-
pathy.
Key exclusion criteria included known hypersensitivity to
ﬂuoroquinolones, tetracycline, or tetracycline derivatives, preg-
nancy or lactation, and the presence of conditions such as diabetic
foot ulcers, prosthetic device infections, osteomyelitis, septic
arthritis, necrotizing fasciitis, and severely impaired arterial blood
supply.2.2. Study design
Patients were equally randomized to one of three treatment
arms: delaﬂoxacin 300 mg IV every 12 h, delaﬂoxacin 450 mg IV
every 12 h, or tigecycline 100 mg IV  1, followed by 50 mg IV every
12 h. To ensure that the types of cSSSI were evenly distributed across
treatment arms, randomization was stratiﬁed by infection type:
abscess, wound infection, or cellulitis. Patients, investigators, and
sponsor personnel were blinded to the identiﬁcation of the study
drug and to randomization assignments until the study was formally
unblinded. Study drug infusions were prepared by a pharmacist who
was unblinded to treatment and who ensured blinding of the
delivered treatment. Treatment was given for 5–14 days, based on
the investigator’s judgment. Wound care management of the cSSSI,
including any surgical procedures, was performed according to the
standard of practice of the investigator or institution. Topical
antibiotics were not permitted at the site of the cSSSI.
2.3. Clinical and microbiological assessments
All patients had an assessment of infection-site signs and
symptoms at all visits. Clinical and microbiological outcomes were
assessed at the test-of-cure (TOC) visit, which was to occur 14–21
days after the last dose of study drug. For a clinical outcome of ‘cure’,
baseline signs and symptoms of infection had to be either completely
resolved or improved to the extent that additional antibiotic
treatment was not necessary. A response of ‘failure’ was assigned
if additional, i.e., non-study antibiotics were required either because
of lack of efﬁcacy after at least 2 days of treatment (i.e., four doses) or
because of treatment-related adverse events (AEs), and/or the need
for surgical intervention at >48 h after study entry. For those
patients who were categorized as clinical cures at the TOC visit, a late
follow-up phone contact was made 28–35 days after the ﬁnal dose of
study drug to determine if the patients had experienced a relapse.
Microbiological assessments were performed at screening, at end of
treatment, if indicated, and, if material for culture was available, at
TOC. Microbiological outcomes were categorized as follows:
‘documented eradicated’ (baseline pathogen was absent in follow-
up cultures of the original site of infection), ‘presumed eradicated’
(no material available for culture and the patient had a clinical
response of ‘cure’), ‘documented persisted’ (baseline pathogen was
present in follow-up cultures of the original site of infection),
‘presumed persisted’ (no material available for culture and the
patient had a clinical response of ‘failure’), and ‘superinfection’
(during therapy, a new pathogen was cultured from the original site
of infection in the presence of signs and/or symptoms of infection).
All microbiological testing was conducted by a single central
laboratory (Euroﬁns Medinet, Chantilly, VA, USA) and included
pathogen identiﬁcation and susceptibility testing performed
according to Clinical and Laboratory Standards Institute stan-
dards.13–15 In addition, all S. aureus isolates were evaluated for
the presence of Panton–Valentine leukocidin (PVL) and mecA
using a multiplex PCR method16 and standard gel electrophoresis
techniques.17
2.4. Safety and tolerability
All patients who received at least one dose of study medication
were evaluated for safety. Safety evaluations included the
incidence of AEs, laboratory test results, vital signs, electrocar-
diographic results, and physical examination ﬁndings.
2.5. Analysis populations
The intent-to-treat (ITT) population included all randomized
patients who received at least one dose of study drug. The modiﬁed
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had a clinical diagnosis of cSSSI, as deﬁned in the protocol. The
clinically evaluable (CE) population comprised those mITT patients
who received at least 80% of the planned course of study drug
therapy, had a TOC visit in the appropriate window, did not receive
any concomitant, systemic antibacterial therapy with activity
against the causative pathogen, and had a culture attempted at the
screening visit. The microbiologically evaluable population includ-
ed all CE patients who had a pathogen isolated at screening that
was susceptible to a study drug.
2.6. Statistics
The primary efﬁcacy analysis was the comparison of the clinical
response rates in the delaﬂoxacin and tigecycline arms in the CE
population at the TOC visit; the clinical response rates in the two
delaﬂoxacin arms were also compared. The Fisher’s exact test was
used for the comparisons.
3. Results
3.1. Patient disposition
One hundred ﬁfty patients were randomized (Figure 1; Table 1).
Overall, 90% of patients completed the study. One hundred nineEnrollm
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Figure 1. Flow diagram of the 150 study patients.
CE, clinically evaluable; cSSSI, complicated skin and skin structure infection; ITT, inte
test-of-cure.
aThe required adequate length was at least eight infusions of study drug or at least foupatients were included in the CE population; the most common
reason for being unevaluable was lack of a TOC visit (25 patients
overall).
3.2. Demographic and baseline characteristics
Patient demographics were similar in the three treatment
groups (Table 2). The mean age was 40 years, two-thirds of the
patients were male, and over 80% were white. The most frequent
diagnosis at entry into the study was cellulitis (36%), followed by
major abscess (33%) and wound infection (31%); most of the
wound infections followed some form of trauma. The mean lesion
size at baseline by digital measurements was 185.9 cm2 (standard
deviation 427.1). Overall, about one-third of enrolled patients had
received prior doses of antibiotic(s) within the constraints of the
exclusion criteria. The mean duration of therapy in the ITT
population was 7.9 days, 7.5 days, and 6.8 days in the delaﬂoxacin
300-mg, delaﬂoxacin 450-mg, and the tigecycline arms, respec-
tively; overall, 92% of patients received therapy for 5–14 days.
One hundred eleven patients (74%) had at least one pathogen
isolated at baseline (Table 3). S. aureus was by far the most
commonly identiﬁed – 96 isolates; of these, 68 (71%) were
methicillin-resistant. Oxacillin resistance correlated well with the
presence of mecA, as detected by PCR; only one isolate was
oxacillin-susceptible but mecA-positive. PVL toxin was detected byent
randomized
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Table 2
Demographic and baseline characteristics (intent-to-treat population)
Characteristics Delaﬂoxacin
300 mg IV
(n = 49)
Delaﬂoxacin
450 mg IV
(n = 51)
Tigecycline
50 mg IV
(n = 50)
Total
(N = 150)
Age, years
Mean (SD) 42.7 (15.10) 37.2 (14.35) 40.4 (13.83) 40.1 (14.51)
Median 42.0 33.0 40.0 40.0
Range 20–83 19–87 18–77 18–87
Gender, n (%)
Male 31 (63.3) 36 (70.6) 35 (70.0) 102 (68.0)
Female 18 (36.7) 15 (29.4) 15 (30.0) 48 (32.0)
Race, n (%)
Caucasian 39 (79.6) 44 (86.3) 40 (80.0) 123 (82.0)
Black 7 (14.3) 4 (7.8) 9 (18.0) 20 (13.3)
Asian 0 1 (2.0) 0 1 (0.7)
Other 3 (6.1) 2 (3.9) 1 (2.0) 6 (4.0)
Diagnosis, n (%)
Cellulitis 19 (38.8) 17 (33.3) 18 (36.0) 54 (36.0)
Major abscess 16 (32.7) 18 (35.3) 16 (32.0) 50 (33.3)
Wound infection 14 (28.6) 16 (31.4) 16 (32.0) 46 (30.7)
Trauma 7 8 10 25
Bite 5 8 6 19
Surgical 2 0 0 0
Received at least 1 prior antibiotic, n (%) 13 (26.5) 18 (35.3) 18 (36.0) 49 (32.7)
IV, intravenous; SD, standard deviation.
Table 1
Patient disposition and analysis populations
n (%) Delaﬂoxacin 300 mg IV Delaﬂoxacin 450 mg IV Tigecycline 50 mg IV
Intent-to-treat 49 (100.0) 51 (100.0) 50 (100.0)
Modiﬁed intent-to-treat 48 (98.0) 51 (100.0) 50 (100.0)
Clinically evaluable 35 (71.4) 40 (78.4) 34 (68.0)
Microbiologically evaluable 27 (55.1) 32 (62.7) 24 (48.0)
Hospitalized for infection under study 2 - 2
IV, intravenous.
Table 3
Gram-positive and Gram-negative pathogens (intent-to-treat population)
n Delaﬂoxacin
300 mg IV
(n = 49)
Delaﬂoxacin
450 mg IV
(n = 51)
Tigecycline
50 mg IV
(n = 50)
Patients with at least 1
pathogen at baseline
35 41 35
Patients with multiple
pathogens at baseline
6 2 3
Gram-positive pathogens 34 42 34
Staphylococcus aureus 31 36 29
MRSA 21 27 20
MSSA 10 9 9
Streptococcus pyogenes 2 1 1
Enterococcus faecalis 0 1 2
Streptococcus agalactiae 0 2 1
Streptococcus group F 0 1 1
Peptostreptococcus asaccharolyticus 0 1 0
Streptococcus group G 1 0 0
Gram-negative pathogens 7 2 4
Acinetobacter baumannii 3 1 0
Acinetobacter junii 0 0 1
Acinetobacter radioresistens 0 0 1
Enterobacter cloacae 1 0 0
Enterobacter intermedius 0 0 1
Klebsiella pneumoniae 1 0 0
Prevotella bivia 0 1 0
Proteus mirabilis 1 0 0
Pseudomonas aeruginosa 0 0 1
Stenotrophomonas maltophilia 1 0 0
IV, intravenous; MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methi-
cillin-susceptible Staphylococcus aureus.
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three patients, one in the delaﬂoxacin 450-mg arm (Streptococcus
group F) and two in the tigecycline arm (Streptococcus group F;
MRSA), had positive blood cultures at baseline. The minimum
inhibitory concentration (MIC) range, MIC50 and MIC90, of dela-
ﬂoxacin and other comparator drugs against baseline S. aureus
isolates is presented in Table 4.
3.3. Clinical outcomes
The clinical cure rates at the TOC visit in the CE population were
94.3% for delaﬂoxacin 300 mg, 92.5% for delaﬂoxacin 450 mg, and
91.2% for tigecycline (Table 5); there were no statistical differences
in outcome between the three arms. All three categories of
infection were effectively treated. All three patients with positive
baseline blood cultures were considered clinical cures.
All three treatments were effective in treating patients with
infections caused by S. aureus (Table 6). Among patients with
infections caused by MRSA, efﬁcacy rates in the delaﬂoxacin arms
were higher than in the tigecycline arm, but differences were not
statistically signiﬁcant. For all three arms, microbiological
eradication rates mirrored the clinical response by pathogen rates.
There was no documented persistence of any baseline pathogens in
any of the treatment arms.
3.4. Safety and tolerability
Delaﬂoxacin was well tolerated at a dose of 300 mg IV every 12 h.
AEs, particularly those of a GI nature, were higher in the other two
treatment arms (Table 7). Infusion-site pain, while noted in seven
Table 4
MIC range, MIC50, and MIC90 of drugs against baseline Staphylococcus aureus
(modiﬁed intent-to-treat population)
Drug Group n MIC range
(mg/ml)
MIC50
(mg/ml)
MIC90
(mg/ml)
Delaﬂoxacin All 95 0.004–0.12 0.03 0.06
MRSA 67 0.004–0.12 0.03 0.06
MSSA 28 0.004–0.12 0.004 0.06
Tigecycline All 95 0.03–0.5 0.12 0.12
MRSA 67 0.06–0.5 0.12 0.12
MSSA 28 0.03–0.25 0.12 0.12
Ciproﬂoxacin All 95 0.12–>32 8 8
MRSA 67 0.12–16 8 16
MSSA 28 0.12–>32 0.25 8
Clindamycin All 95 0.06–>16 0.12 0.12
MRSA 67 0.12–>16 0.12 0.12
MSSA 28 0.06–0.12 0.12 0.12
Daptomycin All 95 0.5–1 0.5 0.5
MRSA 67 0.5–1 0.5 0.5
MSSA 28 0.5–0.5 0.5 0.5
Erythromycin All 95 0.5–>8 >8 >8
MRSA 67 0.5–>8 >8 >8
MSSA 28 0.5–>8 0.5 >8
Gentamicin All 95 0.25–>16 0.5 1
MRSA 67 0.25–>16 0.5 1
MSSA 28 0.25–2 0.5 1
Gentamicin
(high-
level testing)
All 95 500–500 500 500
MRSA 67 500–500 500 500
MSSA 28 500–500 500 500
Levoﬂoxacin All 95 0.12–32 4 4
MRSA 67 0.12–4 4 4
MSSA 28 0.12–32 0.12 4
Linezolid All 95 0.5–2 1 2
MRSA 67 0.5–2 1 1
MSSA 28 0.5–2 1 2
Oxacillin All 95 0.12–>4 >4 >4
MRSA 67 4–>4 >4 >4
MSSA 28 0.12–0.5 0.25 0.5
Vancomycin All 95 0.5–1 0.5 0.5
MRSA 67 0.5–1 0.5 0.5
MSSA 28 0.5–0.5 0.5 0.5
MIC, minimum inhibitory concentration; MRSA, methicillin-resistant Staphylococ-
cus aureus; MSSA, methicillin-susceptible Staphylococcus aureus.
Table 6
Clinical cure rates for Staphylococcus aureus at test-of-cure by baseline pathogen in
the clinically evaluable population
Delaﬂoxacin
300 mg IV
Delaﬂoxacin
450 mg IV
Tigecycline
50 mg IV
Staphylococcus aureus n = 22 n = 27 n = 20
Cure, n (%) 21 (95.5) 25 (92.6) 18 (90.0)
Failure, n (%) 1 (4.5) 2 (7.4) 2 (10.0)
MRSA n = 14 n = 20 n = 14
Cure, n (%) 13 (92.9)a,b 19 (95.0)c 12 (85.7)
Failure, n (%) 1 (7.1) 1 (5.0) 2 (14.3)
MSSA n = 8 n = 7 n = 6
Cure, n (%) 8 (100.0) 6 (85.7) 6 (100.0)
Failure, n (%) - 1 (14.3) -
IV, intravenous; MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methi-
cillin-susceptible Staphylococcus aureus.
a p = 1.0000 vs. tigecycline 50 mg IV by Fisher’s exact test.
b p = 1.0000 vs. delaﬂoxacin 450 mg IV by Fisher’s exact test.
c p = 0.5555 vs. tigecycline 50 mg IV by Fisher’s exact test.
Table 7
Treatment-related adverse events occurring in 5% of patients in any arma
n (%) Delaﬂoxacin
300 mg IV
(n = 49)
Delaﬂoxacin
450 mg IV
(n = 51)
Tigecycline
50 mg IV
(n = 50)
Any treatment-
related AE
22 (44.9) 32 (62.7) 36 (72.0)
Nausea 6 (12.2) 13 (25.5) 23 (46.0)
Diarrhea 5 (10.2) 12 (23.5) 5 (10.0)
ALT increased 3 (6.1) 0 0
Headache 2 (4.1) 4 (7.8) 6 (12.0)
Insomnia 2 (4.1) 1 (2.0) 2 (4.0)
Constipation 1 (2.0) 0 4 (8.0)
Fatigue 1 (2.0) 4 (7.8) 0
Vomiting 0 6 (11.8) 14 (28.0)
Infusion-site pain 0 7 (13.7) 0
Dizziness 0 1 (2.0) 4 (8.0)
Rash 0 2 (3.9) 3 (6.0)
AE, adverse event; ALT, alanine aminotransferase; IV, intravenous.
a Events are presented in decreasing order of frequency for the delaﬂoxacin
300-mg arm.
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arm. Five patients, two in the delaﬂoxacin 450-mg arm and three in
the tigecycline arm, discontinued the study because of AEs. Seven
patients experienced a total of eight serious adverse events (SAEs)
during the study (one in the delaﬂoxacin 300-mg arm, three in the
delaﬂoxacin 450-mg arm, and four in the tigecycline arm); of these,
only one—a generalized seizure in a 53-year-old male in the
delaﬂoxacin 450-mg arm—was judged to be possibly related to
study therapy. There were no deaths in the study.
In a review of routine chemistry evaluations, 11 delaﬂoxacin-
treated patients (two in the 300-mg arm and nine in the 450-mg
arm) and one tigecycline-treated patient had below-normal glucose
values after having had normal values at baseline. With oneTable 5
Clinical cure rates at test-of-cure in the clinically evaluable population
Delaﬂoxacin
300 mg IV
Delaﬂoxacin
450 mg IV
Tigecycline
50 mg IV
Total, n/N (%) 33/35 (94.3)a,b 37/40 (92.5)c 31/34 (91.2)
Cellulitis, n/N (%) 12/13 (92.3) 14/14 (100) 11/11 (100)
Abscess, n/N (%) 12/12 (100) 11/13 (84.6) 11/13 (84.6)
Wound infection, n/N (%) 9/10 (90.0) 12/13 (92.3) 9/10 (90.0)
IV, intravenous.
a p = 0.6733 vs. tigecycline 50 mg IV by Fisher’s exact test.
b p = 1.0000 vs. delaﬂoxacin 450 mg IV by Fisher’s exact test.
c p = 1.0000 vs. tigecycline 50 mg IV by Fisher’s exact test.exception, all of the low values among delaﬂoxacin-treated patients
occurred during the dosing period; one patient’s low value was noted
at the TOC visit. Only one patient, in the 450-mg arm, had a reported
AE of hypoglycemia; the remaining patients were asymptomatic.
None of the patients had an ongoing history of diabetes.
4. Discussion
This is the ﬁrst study exploring the safety and efﬁcacy of IV
delaﬂoxacin in patients with cSSSIs. MRSA was the most frequently
identiﬁed pathogen, accounting for over half of all baseline
bacterial isolates collected (68/123, 55.3%), consistent with the
epidemiology of Gram-positive bacteria and complicated skin and
soft-tissue infections.18,19 Delaﬂoxacin demonstrated potent in
vitro activity against these strains (MIC90 of 0.06 mg/ml). Both
doses of delaﬂoxacin met the primary endpoints in the treatment
of cSSSIs, including the three types of skin infections enrolled in
this study, and both were comparable with tigecycline. All three
regimens were effective against S. aureus, including methicillin-
resistant strains, and in no instance were staphylococcal isolates
found to have persisted following treatment. The smaller numbers
of infections caused by various streptococcal species and Gram-
negative pathogens were also treated successfully.
GI disturbances—nausea, vomiting, and diarrhea—were among
the most frequently reported AEs in the study. Both delaﬂoxacin
groups had a lower incidence of GI side effects than the tigecycline
W. O’Riordan et al. / International Journal of Infectious Diseases 30 (2015) 67–7372group; and in the delaﬂoxacin groups, the incidence of GI AEs
appeared to be dose-related. Infusion-site reactions, e.g., pain or
phlebitis, were noted in the high-dose delaﬂoxacin group only.
Of the eight SAEs reported in the study, only one—a generalized
seizure in a patient in the high-dose delaﬂoxacin group—was
considered possibly related to delaﬂoxacin. The patient was a 53-
year-old white male with a past medical history notable for
hepatitis C and an addiction to pain medications. He was enrolled
in the study with a left chest wall abscess and had a witnessed
seizure following a dose of delaﬂoxacin on day 3 of the study.
During the subsequent evaluation, he disclosed for the ﬁrst time
that he had had seizures in the past, but had never had a medical
workup of any kind. A computed tomography scan performed the
day after the event was unremarkable, as were an electroenceph-
alogram and magnetic resonance imaging approximately 3 weeks
later. No deﬁnitive cause for the seizure was identiﬁed and the
investigator considered the event possibly related to the study
drug.
Fluoroquinolones have been associated with dysglycemia in
both diabetic and non-diabetic patients, and the risk of a clinically
relevant dysglycemic event appears to differ among ﬂuoroquino-
lones.20,21 As part of the routine chemistry review, low serum
glucose values were observed in 11 delaﬂoxacin-treated patients
(nine patients in the 450-mg group and three patients in the 300-
mg group) and in one tigecycline-treated patient. Only one patient
in the 450-mg delaﬂoxacin group reported an AE of hypoglycemia.
The mechanism for the hypoglycemia is believed to be stimulation
of insulin release via interference with the K+/ATPase pump in
pancreatic beta cells, although this was not observed in preclinical
studies of delaﬂoxacin. However, continued monitoring of serum
glucose is warranted in future studies of delaﬂoxacin.
This study was designed in accordance with FDA guidance
issued in 1998.22 In 2013, the FDA issued a new draft guidance
document23 proposing new terminology for the infections in
question, acute bacterial skin and skin-structure infections
(ABSSSI), as well as a new primary efﬁcacy endpoint where
treatment can be assessed by evaluating if there is an at least 20%
reduction in lesion size documented at 48–72 h after starting
therapy. Resolution of the infection after completion of therapy is
now a suggested secondary endpoint. The new endpoint has been
assessed in a more recently completed phase 2b study of
delaﬂoxacin in ABSSSI24,25 and has been incorporated into the
design of ongoing phase 3 studies of delaﬂoxacin 300 mg as well.
A limitation of this study was the ability to enroll infections
under fewer severity constraints that exist today: only four
patients required hospitalization for management of their infec-
tions. A key feature of the deﬁnitions of ABSSSI in the latest FDA
guidance is the requirement that the infections under study have a
minimum surface area of 75 cm2. Such a requirement was not in
place in the current study; however, many of the lesions within
this study met that requirement.
The 300-mg dose of delaﬂoxacin, given its clinical and
microbiological effect and its tolerability proﬁle, is currently being
evaluated in larger phase 3 studies that not only incorporate the
latest deﬁnitions of infection type and clinical response, but also
evaluate both the IV and oral formulations.
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